AVALIAÇÃO DO EFEITO DA SUPLEMENTAÇÃO COM COENZIMA-Q10 SOBRE A RESISTÊNCIA INSULÍNICA EM MULHERES OBESAS PORTADORAS DA SÍNDROME DOS OVÁRIOS POLICÍSTICOS
Polycystic Ovary Syndrome. Coenzyme Q10. Insulin resistance.
Polycystic Ovary Syndrome (PCOS) is a multifactorial endocrinopathy, of undefined origin and affecting a considerable portion of the female reproductive age population. Due to their characteristic metabolic profile, they may present dyslipidemia, obesity, metabolic syndrome (MS), insulin resistance (IR), these factors may contribute to the development of oxidative stress (EO). This OE generated by the excess of reactive oxygen species favors the development of complications, such as atherosclerosis, inflammatory and cardiac diseases, among others. Considering this fact, coenzyme Q10 is a benzoquinone that plays an important role in the elimination of free radicals and inhibition of lipid and protein oxidation. Therefore, this study aimed to evaluate the effect of supplementation with coenzyme Q10 on insulin resistance in obese women with SOP. The study population consisted of 60 obese women, aged between 20 and 40 years with and without a diagnosis of PCOS. For comparative analysis the patients were divided into two groups: Case (obese with SOP - n = 30); Control (obese without SOP - n = 30). Both groups received coenzyme Q10 and obesity was characterized by body mass index (BMI), and the cut-off point was . 30.0 kg/m. In follow-up, women were evaluated for clinical, biochemical and hormonal parameters. Statistical analysis of the data was performed with the statistical package SPSSc 22.0. IR was verified in 76.7% of the case group and 80% of the control group. Comparative analysis between the pre and post-intervention SOP groups showed significant differences in relation to mass (91.1 vs. 89.9 kg), glucose 120 minutes (138 vs. 122.5 mg/dL), insulin (16.2 vs. 10.7 ƒÊUI/mL), HOMA-IR (3.67 vs. 2.31) and QUICKI (0.31 vs. 0.30). In addition, significance was observed in the lipid and also hormonal profiles, such as follicle stimulating hormone (5.4 vs. 6.0 IU/mL), luteinizing hormone (6.3 vs. 4.5 IU/mL), testosterone (32.1 vs. 22.0 ng/dL) and progesterone (0.20 vs. 0.35 ng/dL). In relation to the control group, it was possible to observe significant results in relation to biochemical and hormonal parameters. Thus, the intervention with coenzyme Q10 can promote beneficial effects in relation to the main metabolic and hormonal alterations that are present in PCOS.